Targeted Oncology50m
DSMB Approves Continued GOBLET Cohort 5 Enrollment in Pancreatic Cancer
Enrollment in cohort 5 of the phase 1/2 GOBLET study will resume after the Data Safety Monitoring Board’s safety review.
Targeted Oncology2h
Daratumumab Quadruplet Improves Outcomes in Transplant-Ineligible Myeloma
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the CEPHEUS trial results and impact on frontline treatment in ...
Targeted Oncology20h
CEPHEUS Trial Results: Daratumumab-VRd in Transplant-Ineligible Myeloma
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the results and potential impact from the phase 3 CEPHEUS trial.
Targeted Oncology22h
ASH 2024 Preview for Community Oncologists: The Show and After Show
Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for community oncologists to look out for ...
Targeted Oncology18h
Therapies With Different Mechanisms of Action Available for Low-Risk MDS
Bertrand Y. Tuan, MD, hematologist/oncologist at Pacific Hematology Oncology Associates and California Pacific Medical Center ...
Targeted Oncology23h
TERN-701 Shows Promising Early Results in Heavily Pre-Treated CML
TERN-701 showed promising early results, with significant molecular responses and a strong safety profile in heavily ...